Novartis holds back the copycat brigade's attack on its top drug franchise — for now
A federal judge has put a generic challenge to Novartis’ blockbuster multiple sclerosis drug Gilenya on hold while a patent fight plays out in court.
Judge Leonard P. Stark issued a temporary injunction earlier this week, forcing Mylan, Dr. Reddy’s Laboratories and Aurobindo Pharma to shelve their launch plans to allow the patent fight to proceed. He ruled that allowing the generics into the market now would permanently slash the price for Novartis, even if it prevails.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
